Shares of Simulations Plus, Inc. (NASDAQ:SLP) have received an average broker rating score of 2.00 (Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation.
Analysts have set a twelve-month consensus price objective of $21.50 for the company and are predicting that the company will post $0.15 earnings per share for the current quarter, according to Zacks. Zacks has also given Simulations Plus an industry rank of 10 out of 255 based on the ratings given to its competitors.
Several analysts recently issued reports on the stock. BidaskClub lowered shares of Simulations Plus from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 4th. Zacks Investment Research upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a report on Wednesday, March 20th. Finally, Taglich Brothers lowered shares of Simulations Plus from a “buy” rating to a “speculative buy” rating in a report on Wednesday, January 16th.
NASDAQ SLP opened at $22.61 on Friday. Simulations Plus has a 52 week low of $16.26 and a 52 week high of $23.95. The firm has a market cap of $348.50 million, a PE ratio of 45.22 and a beta of -0.50.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Tuesday, April 9th. The technology company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. Simulations Plus had a return on equity of 23.23% and a net margin of 23.61%. The business had revenue of $8.47 million for the quarter, compared to analyst estimates of $8.10 million. As a group, research analysts expect that Simulations Plus will post 0.43 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 24th will be issued a $0.06 dividend. The ex-dividend date of this dividend is Tuesday, April 23rd. This represents a $0.24 annualized dividend and a yield of 1.06%. Simulations Plus’s dividend payout ratio (DPR) is currently 48.00%.
In other Simulations Plus news, Director Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $20.65, for a total value of $382,025.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 55,500 shares of company stock worth $1,109,075. 31.57% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. grew its position in Simulations Plus by 156.9% in the 4th quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after acquiring an additional 1,290 shares in the last quarter. Bessemer Group Inc. grew its position in Simulations Plus by 8.6% in the 4th quarter. Bessemer Group Inc. now owns 31,700 shares of the technology company’s stock valued at $631,000 after acquiring an additional 2,500 shares in the last quarter. Wells Fargo & Company MN grew its position in Simulations Plus by 11.4% in the 3rd quarter. Wells Fargo & Company MN now owns 31,783 shares of the technology company’s stock valued at $643,000 after acquiring an additional 3,249 shares in the last quarter. Martingale Asset Management L P grew its position in Simulations Plus by 4.7% in the 4th quarter. Martingale Asset Management L P now owns 73,608 shares of the technology company’s stock valued at $1,465,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Simulations Plus by 65.7% in the 4th quarter. Bank of America Corp DE now owns 8,754 shares of the technology company’s stock valued at $174,000 after acquiring an additional 3,471 shares in the last quarter. 40.74% of the stock is owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Recommended Story: Asset Allocation Models, Which is Right For You?
Get a free copy of the Zacks research report on Simulations Plus (SLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.